Medical bottles and syringes are seen with the logo of the new Nordisk shown on the screen in the background.
Nurphoto | Nurphoto | Getty Images
Danish pharmaceutical Behemoth Novo Nordisk On Wednesday, in the fourth quarter, he reported on a net profit from the expected, due to the increase in demand for his obesity drugs.
The net profit for the fourth quarter came to 28.23 billion of the Danish crown ($ 3.98 billion), opposite $ 26.09 billion.
The year -round net profit reached 100.99 billion of the Danish crown, and also won estimates of 99.14 billion of the Danish crown for 2024.
The drug manufacturer has published 107% Annual increase in Wegovy sales at 19.87 billion of the Danish Crown (2.76 billion USD) in three months by the end of December, there was a little missing 20.02 billion forecasts by Danish Kroner’s forecast by analysts in a survey of facts late Tuesday.
Novo Nordisk rode a wave of growing global demand for obesity of GLP-1 agonist obesity. GLP-1S, which make up the basis of the new Wegovy and rivals Eli LillyZupbound, the work mimicking a hormone called Glucagon Peptid-1, which suppresses appetite.
Investors are now looking for updates about other obesity candidates, including her hot expected experimental treatment of Cagrisema. The results of the attempts in Kagrisem in the late phase disappointed Markets in December after showing an average decrease in weight of 22.7%, under 25% newly forecast.
The results of the experiments have done a blow to the expectations that Cagrisema will appear as a new cure for the obesity of the next generation, combining semaglutide-active ingredient in Wegovy-S amilin analog Cagrilintide, and An innate form of weight loss treatment.
However, positive The results of an early stage Due to his one weekly drug for the obesity of Amycretina, which is similarly used by the pancreatic hormone Amilin, he brought in stock last month.
This is the story of the news and will be updated soon.